retatrutide triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% What Is Retatrutide? Triple Agonist
Pay in 4 interest-free payments of $5.99 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16



















01585-5/asset/19c5e1a6-3ebc-453e-87c3-a11a7b2d6a64/main.assets/gr1.gif)









